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 Chapter 8 
 International Collaboration for Global Public 
Health 
 Eric  M.  Meslin and  Ibrahim  Garba 
8.1  Introduction 
 There is a long tradition of global  collaboration in biomedicine and public health. 
Examples range from medical outposts in rural communities run by foreign mis-
sionaries (Good  1991 ) to the early  infectious disease programs of the  Rockefeller 
Foundation (Fosdick  1989 ) and from medical services and training programs for 
indigenous  populations set up by colonial authorities (Marks  1997 ) to the  Pan 
American Health Organization (PAHO) established by a collective of sovereign 
 governments (Cueto  2007 ). 
 Two complementary sets of factors provide context for understanding collabora-
tion in  global public health : fi rst, the factors that inform  globalization generally and 
 global  health specifi cally; second, the factors that shape ethical  standards for global 
health programs generally and global health  research  specifi cally. Good examples 
of both factors are refl ected in this chapter’s case studies. 
 The opinions, fi ndings, and conclusions of the authors do not necessarily refl ect the offi cial 
position, views, or policies of the editors, the editors’ host institutions, or the authors’ host 
institutions. 
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8.2  The Rise of  Globalization and  Global Health 
 Collaboration in global health, as we know it today, began taking shape after World 
War II when new  laws and institutions were established to govern relations among 
countries. The war’s end was marked by efforts to establish a body that would 
facilitate peaceful relations among member countries. In 1945, the  United Nations 
(U.N.) was established “to save succeeding generations from the scourge of war” 
and to “promote social progress and better  standards  of life” (U.N.  1945 ). Various 
U.N. agencies were set up to realize these goals—most prominently the  World 
Health Organization (WHO) , founded in 1948 “to act as the directing and 
coordinating authority on international health work” (WHO  1948 ). 1 Yet even as 
these institutions were being established, their ability to encourage  international 
collaboration was hampered in two ways.
 First , most  low- and middle-income countries (LMICs) , which bear the bulk of 
today’s global  disease burden , were under  colonial rule for the fi rst decade of the 
U.N.’s existence. Hence, these countries were unrepresented in the new organiza-
tion. In later years, the  principle of  self-determination (i.e., the right of “peoples” to 
govern themselves and choose their developmental priorities) and the efforts of 
nationalist movements secured  political independence and membership in the inter-
national community. In effect, the  governments of these countries were authorized 
under international  law to represent their  populations in relations with other govern-
ments, thereby enabling equitable partnerships, even in matters of health. 
 Second, the escalation of the  Cold War in the founding years of the U.N. intro-
duced ideological rivalries into its workings. These rivalries often impeded coordi-
nated actions involving health. For example, the 1950s and 1960s were marked by 
the superpowers’ competitive attempts to eradicate specifi c (often communicable) 
diseases (e.g., the  United States targeted malaria while the Soviet Union focused on 
smallpox) (WHO  2008b ). This selective, disease-specifi c vertical approach  con-
fl icted with the realization in the 1970s that primary health care was a vital compo-
nent of a national health system. The latter approach defi ned “health” broadly, 
recognizing it as a right and acknowledging the impact of socioeconomic factors on 
wellness (WHO  1978 ). The emphasis on primary health care became critical for 
 governments of newly independent countries faced with the task of expanding 
health systems that under  colonial rule had catered to a narrow, privileged segment 
of the  population (WHO  2008a ). However, ideological disputes over government’s 
role in society and the  policies of the  International Monetary Fund (IMF) , which 
favored privatization of certain public services (Stuckler and Basu  2009 ), neglected 
the primary health care approach (WHO  2008b ). The  Cold War also infl uenced pat-
terns of  global health  collaboration , particularly among members of feuding coali-
tions that continued to support ideologic allies (Feldbaum et al.  2010 ). 
1  Other U.N.-affi liated agencies not directly related to health but infl uencing collaboration in public 
health include the International Monetary Fund ,  World Bank , and World Trade Organization. 
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 The  fall of the Berlin Wall in 1989 and the collapse of the Soviet Union shortly 
thereafter marked the end of the  Cold War . These events led more countries to adopt 
liberal and capitalist  principles . Other developments—advances in communications 
(most notably, the Internet) and greater  trade and travel across borders—intensifi ed 
exchanges among national communities. Collectively referred to as  the process of 
 globalization , 2 these changes altered the global context for public health 
 collaboration . 
 On the one hand, the absence of a drawn-out ideological battle led to constructive 
deliberation and global action in public health. For example, in 2000, all members 
of the U.N. General Assembly declared their commitment to achieving eight objec-
tives (the Millennium Development Goals) by 2015—half of which pertained to 
health. Also signifi cant were widespread efforts to address the  HIV/AIDS epidemic 
through such mechanisms as the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 3 and the more recently established  Global Fund to Fight AIDS, 
Tuberculosis and Malaria. 4 
 On the other  hand , the growing infl uence of liberal and capitalist  principles in the 
global environment of the 1990s affected the extent to which  governments (espe-
cially those of  LMICs ) were involved and able to collaborate in public health. These 
changes included
 … an increasing reliance upon the free market; a signifi cant growth in the infl uence of 
international fi nancial markets and institutions in determining national  policies ; cutbacks in 
public sector spending; the privatization of functions previously considered to be the exclu-
sive domain of the state; and the deregulation of a range of activities with a view to facilitat-
ing investment and rewarding entrepreneurial initiative. These trends serve to reduce the 
role of the state in economic affairs, and at the same time increase the role and responsibili-
ties of private (non-state) actors, especially those in corporate business, but also those in 
civil society…. (WHO  2002 ) 
 Generally associated with neoliberal  principles , the changes discussed above 
have reduced  governments ’ public policy role. These developments notwithstand-
ing, there remain compelling arguments for deliberate and sustained engagement by 
governments in the interest of  global public health . Three are discussed below. 
8.2.1  Collective Health 
 The fi rst argument is that even with their reduced profi le in national health systems, 
 governments continue to bear primary responsibility for  population health . 
Individual citizens can take responsibility for personal health, but certain health 
2  Defi nitions of  globalization vary by disciplinary focus. Richard Labonté ( 2004 ) describes global-
ization as “a process by which nations, businesses, and people are becoming more connected and 
interdependent across the globe through increased economic integration and communication 
exchange, cultural diffusion (especially of  Western culture), and travel.” 
3  See  http://www.unaids.org/en/ 
4  See  http://www.theglobalfund.org/en/ 
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 benefi ts (e.g., clean air, safe roads, potable water) can be secured only through orga-
nized, collective efforts generally involving the exercise of public authority. As 
such, in the interest of global  health , a country’s public health institutions should be 
robust—equipped to protect  population health , reduce disease, and administer pro-
grams that save money and lives (Frieden and Koplan  2010 ). This case needs to be 
made for  LMICs especially; otherwise, neoliberal  principles guiding  globalization 
may further weaken emergent, poorly governed, or underfunded health systems. 
 Indeed, the exercise (or failure) of public authority infl uence all ethical issues 
presented by the cases in this chapter. In Jensen and Gaie’s case, an  LMIC  govern-
ment has neither passed legislation nor provided support that would effectively pre-
vent  discrimination against citizens seeking  HIV services. In Zinner’s case, an 
 international aid worker must make diffi cult decisions about who gets preventive 
 HIV/AIDS  treatment in an African community characterized by a neglected, poorly 
funded health system. In Timms’ case, a physician encounters an ethical challenge 
brought about by the underdeveloped health infrastructure in  India , the govern-
ment’s lax  enforcement of research  regulations , and the substantial infl uence of 
large foreign  pharmaceutical companies on national  policy . In List and Boyd’s case, 
a foreign researcher must decide whether there is an ethical  obligation to expose an 
African government’s avoidable failure to prevent a TB medication  stock-out . 
Under question in Millum’s case is the degree to which both the U.N. (as a collec-
tive body of  governments carrying out a humanitarian intervention) and the Haitian 
government (as the provider of health infrastructure for its citizens) can be held 
morally or legally liable for a cholera outbreak. In Al-Faisal, Hussain, and Sen’s 
case, a public health expert testifying before a U.N. Commission must weigh in on 
the extent to which (1) foreign governments are obliged to minimize  harm to the 
health of Syrians and Iraqis when applying  sanctions and (2) Syrian and Iraqi gov-
ernments are obliged to conduct a foreign  policy that does not jeopardize the health 
of their citizens. A U.S.-based researcher grapples in Lee, Kleinfeld, and Glassford’s 
case with the question of whether she can ethically justify publishing a paper based 
on data obtained from two African countries whose governments have neither insti-
tutional review  boards nor national research  guidelines . 
8.2.2  Coordination 
 The second argument favoring  active  engagement of  governments in national health 
systems is their longstanding ability to enter binding legal agreements with each 
other and other  stakeholders . A government’s continued involvement is indispens-
able to shaping broad-based and sustainable solutions to the challenges of  global 
public health . The broad scope of a government’s responsibilities (and authority 
associated with performing these responsibilities) enables it to coordinate public 
health efforts involving public, private, and civic institutions. The importance of 
governmental involvement was crystallized in the words of former WHO Director 
General, Gro Harlem Brundtland, as the 2003 WHO  Framework Convention on 
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Tobacco Control was being drafted: “Tobacco control cannot succeed solely through 
the efforts of individual  governments , national NGOs (nongovernmental organiza-
tions) ,  and media advocates. We need an international response to an international 
problem” (Bodansky  1999 ). Tackling one of the world’s leading causes of prevent-
able death (i.e.,  smoking ), the Framework Convention adopts a comprehensive 
strategy that has been signed by the governments of 168 countries. 5 
 With completion of the human genome and development of various technologies 
to use it, interest in DNA repositories has surged (Kaye et al.  2009 ). The develop-
ment and increasing use of biorepositories of DNA, tissues, and other biological 
materials in institutions worldwide present far-reaching ethical challenges. Some 
challenges, such as those resulting from the collection and use of dried blood spots 
(Hendrix et al.  2013 ) or from regular  surveillance like the U.S.  Centers for Disease 
Control and Prevention (CDC)  HIV surveillance projects, are recurrent and famil-
iar. 6 When specimens must be shared in the context of  collaborative public health 
emergency  response and planning, the challenges can take on greater urgency. Such 
emergency collaborative sharing has occurred with virus strains for  pandemic infl u-
enza planning 7 and with the sequencing of the SARS coronavirus jointly undertaken 
by researchers from Canada, Hong Kong, Taipei, the  United States , and Vietnam 
during the global outbreak (Tong et al.  2004 ). Similarly, the sharing of data and 
health  information has long been a source of ethical and legal commentary and is 
widely viewed as desirable ethical behavior with demonstrable scientifi c benefi t 
(Committee on National Statistics  1985 ; Benkler and Nissenbaum  2006 ). 
8.2.3  Accountability 
 The third  argument supporting  government engagement in  global public health is 
based on democratic theory. Put simply, a country’s citizens can hold their govern-
ments accountable for failure to meet health commitments. In contrast to govern-
ments that are accountable to their entire  populations , NGO  stakeholders in  global 
health answer to narrower constituencies (i.e., corporations to their stockholders, 
NGOs to their funders, and foreign health organizations to their home govern-
ments). Because public health is of general concern, a level of accountability is 
essential for the entire health system to function properly. The involvement of gov-
ernments is, therefore, critical both to ensure the widest  participation possible in 
formulating health  policies and to sustain such policies despite shifting interests or 
diminishing profi ts of partners. 
 Setting aside the issue of relative advantages or demerits, the diminished role of 
 governments in  global public health —especially governments of  LMICs —creates 
5  See  http://www.who.int/fctc/signatories_parties/en/index.html 
6  See  http://www.cdph.ca.gov/programs/aids/Pages/TOASurv.aspx 
7  See  http://www.ip-watch.org/2013/05/27/world-health-assembly-pandemic-fl u-framework-
clears-committee/ 
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room for others to enter the fi eld. Entrants include public institutions (e.g., interna-
tional intergovernmental  bodies , governments of emerging economies); NGOs 
(e.g., development and relief agencies, academic health partnerships, faith-based 
initiatives); private entities (e.g., corporations, philanthropies, individuals); and 
hybrid entities that pool resources and expertise from public, nongovernmental, and 
private  stakeholders (e.g., The  Global Fund to Fight AIDS, Tuberculosis and 
Malaria). Each entrant to the  global health environment plays a unique role. Some 
take direct action by providing care, some facilitate and leverage the work of others, 
and some effect change in  policies to cultivate better and closer  collaboration . All 
undertake some form of partnership activity. 
 Essentially, rather than being merely an instrument of foreign policy and diplo-
macy or a means to technical aid between governments, collaboration in health has 
grown into a global endeavor involving many actors and  stakeholders (Elmendorf 
 2010 ). The declining role of governments in public policy presents special chal-
lenges for  global public health , and the proliferation of stakeholders makes the for-
mation of partnerships more demanding and critical. As  such , effective ethical 
frameworks that can serve as guides for planning and also as arbiters between com-
peting  values are indispensable. 
8.3  Ethics Frameworks for Global Health 
 Complementing this  political history has been an equally comprehensive set of 
approaches, each of which provides a moral foundation for defending actions,  poli-
cies , and decisions in global health. Foremost among these are principle-based 
approaches,  human-rights frameworks, and  social determinants of health (SDH) , 
although other approaches have been suggested (Ruger  2009 ). 
8.3.1  Principles and Benchmarks 
 The debate arising from the 1997 AIDS Clinical Trial Group Study 076 (ACTG- 
076) to reduce maternal–fetal transmission of  HIV served many purposes. Among 
the most useful was the attention focused on how ethical arguments are applied to 
substantive problems in global health (Lurie and Wolfe  1997 ; Varmus and Satcher 
 1997 ). Until then, most bioethical refl ection had concentrated on domestic topics, 
aside from revisions to the  Declaration of Helsinki and other documents. ACTG-
076,  however , energized discussion about, among other things, the nature of ethical 
 obligations and commitments to groups, countries, and regions—whether of 
researchers to research  participants , of science to society, or sponsors to host coun-
tries (Shapiro and Meslin  2001 ).  Accusations  of parachute research and double 
 standards abounded, leading many to rethink the applicability of accepted ethical 
principles and practices and to consider new contexts. They also questioned whether 
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researchers, sponsors, or  governments owed any continuing  obligation of care to 
research participants at the end of a  study . The  bioethics principles developed over 
three decades by Beauchamp and Childress ( 2009 ) provided a formidable founda-
tion upon which debates about research and health care could be played out—even 
in the face of critiques about their adequacy and suffi ciency as moral theory (Clauser 
and Gert  1990 ). Other principles have been recommended by scholars (Lavery et al. 
 2007 ) and  organizations (United Nations Educational, Scientifi c and Cultural 
Organization [UNESCO]  2005 ), but even proponents of principle-based approaches 
recognized that more was needed to meet challenges in emerging areas of science 
(e.g., public health genomics and transborder studies) (Lavery et al.  2007 ; Emanuel 
et al.  2008 ; Macklin  2008 ). 
 Indeed, early in the tenure of the  National Bioethics Advisory Commission 
(NBAC) that later reported on the ethics of  clinical trials (NBAC  2001 ), Ezekiel 
 Emanuel  proposed that the Commission review the  Belmont Report principles. He 
urged the Commission to adopt a new principle to its canon of  bioethics , namely a 
principle of c ommunity to accommodate ethical issues arising from the recruitment 
of groups. Although the Commission did not adopt this principle, Emanuel’s pro-
posal has since emerged as one of several benchmarks for assessing ethical accept-
ability of clinical  research in developing countries (Emanuel et al.  2004 ). More 
relevantly, the concept of community engagement and  participation has taken on a 
greater role in discussions about the importance of partnerships. 
 The cases by Timms and by Lee, Kleinfeld, and Glassford illustrate the utility of 
using ethical principles to frame the unique challenges of  global  collaboration in 
 biomedical research . Timms raises a critical issue about whether a  multinational 
pharmaceutical  company conducting  clinical trials in an  LMIC is responsible for 
 harms sustained by research participants during its investigations. The ACTG-076 
debate has broadened the question of  accountability , recognizing that impoverished 
and poorly educated  populations living with underdeveloped regulatory, health, and 
social service infrastructures must prompt reassessment of a  multinational trial 
sponsor’s ethical  obligations . Such reassessment has focused, naturally, on mea-
sures that prevent exploitation of vulnerable and desperate individuals in  LMICs 
(e.g., appropriate  informed consent , vigilant recruitment practices). But it has also 
raised the question of whether foreign sponsors and researchers have an ethical 
 obligation to the host community or country supplying the large and diverse recruit-
ment pool at comparatively lower  cost . 
 In the case  described  by Lee, Kleinfeld, and Glassford, a researcher must deter-
mine, apart from questions of scientifi c validity and potential health utility, whether 
proper  informed consent was obtained in the acquisition of data and tissue samples 
being used for  research on which she has been invited to  collaborate . These data and 
specimens were gathered using various  consent methods from six African countries, 
none of which had ethics review boards or national research  guidelines . Her collabo-
rator assures her that the consent modalities applied, though varying widely, were 
appropriate to the settings in which they were used. In deciding whether to coauthor 
an article based on acquired data, the researcher must consider how (or whether) the 
requirements of  informed consent , a foundational principle of ethical research, can 
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be met in different global settings, particularly those characterized by cultural or 
linguistic differences, low health literacy, and absence of regulatory infrastructure. 
8.3.2  Human Rights 
 Human rights constitute a compelling ethical framework for global collaboration. 
Based on an ethical vision discernable in early Greco-Roman writings, these  prin-
ciples matured in the work of such social contract  theorists as Thomas  Hobbes , 
Jean-Jacques  Rousseau , and John  Locke . The modern view of human rights presup-
poses that all persons, simply for being human, have inherent dignity. This dignity 
constitutes the normative foundation for people having certain inalienable rights. 
The terms  inherent  and  inalienable mean such dignity and rights belong to people 
naturally and are, certainly,  not bestowed by a  political authority . According to 
 human rights theory, a political authority has no ethical basis for arbitrarily depriv-
ing individuals of these rights (not having granted such rights in the fi rst place). But 
because some needs are common and not all goals can be met individually, people 
choose to surrender certain rights to a public authority established to ensure these 
ends are realized. Hence, a  government 
 … exists to ensure the well-being of the individuals who give up certain rights in exchange 
for certain protections and benefi ts […]. The same applies to the community they jointly 
establish. From this analysis, the traditional roles of  government include such things as col-
lective security, the administration of  justice , the protection of property and […] the  promo-
tion of the public’s health…. (Meslin and Garba  2011 ) 
 This theoretical sketch provides a backdrop to the 1948  U.N.  Universal 
Declaration of Human Rights (UDHR) , the ethical cornerstone of the  human rights 
system since the end of World War II. Using  human dignity as its starting point, the 
UDHR codifi es a unifi ed ethical vision for preserving a peaceful and just interna-
tional order while also emphasizing “social progress and better  standards of life” 
(U.N.  1948 ). Correspondingly, the UDHR contains rights that are broadly  political 
(e.g., fair trial, free speech,  freedom of religion) and others that focus on economic 
and  social conditions (e.g., housing, education, health). 
 As discussed previously, however, the  Cold War introduced ideological rivalries 
into the U.N., rifts that split the unifi ed ethical vision of the UDHR into two treaties: 
the  International Covenant on Civil and Political Rights (ICCPR) (U.N.  1966a ) and 
the  International Covenant on Economic, Social and Cultural Rights (ICESCR) 
(U.N.  1966b ). 8 The two treaties refl ected the priorities of the  opposing  sides—the 
 ICCPR advocated by the U.S.-led capitalist alliance and the  ICESCR championed 
by the U.S.S.R.-led communist bloc. Having two treaties hindered the deployment 
of  human rights as an effective ethical framework for health  collaboration during 
the latter half of the twentieth century. 
8 Article 12 of the  ICESCR codifi es the right to health. 
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 As the  Cold War abated, the global community adopted a more holistic approach 
to  human rights , including the  right to health . This was captured in the 1993 
 U.N. Vienna Declaration and Programme of Action , a document that reaffi rmed 
human rights as “universal, indivisible, and interdependent and interrelated” (U.N. 
 1993 ). The Vienna Declaration laid the foundation for the creation of the  Offi ce the 
United Nations High Commissioner for Human Rights (OHCHR) , an agency that 
oversees the promotion and protection of  human rights throughout the U.N.  system . 
Moreover, the  U.N. Human Rights Council (HRC) , 9 through its special procedures, 
appoints independent experts (or “special rapporteurs”) 10 to report on areas of con-
cern, including such health-related themes as food, physical and  mental health , 
adequate housing and extreme poverty, and healthy and sustainable environments. 11 
As noted previously, this holistic approach was also refl ected in the adoption of the 
Millennium Development  Goals (most of which are related to health) and exempli-
fi ed in the coordinated approach to tackling  HIV/AIDS . The health and  human 
rights  movement , which gained traction during the global discussion on sexual and 
reproductive health, fi rmly took root once health  professionals responded to the 
peculiar challenges of treating HIV-positive people facing  discrimination (Gruskin 
et al.  2007 ; Mann  1997 ). 
 Quite apart from the scarcity of fi scal resources that often plague  LMIC  govern-
ments , other challenges preclude adopting an integrated approach to the  right to 
health . For example, a long-standing argument is that the right to health as codifi ed 
in the International Covenant on Economic, Social and Cultural  Rights attaches to 
individuals and is, hence, unsuited for effectively achieving public health objec-
tives, goals that by defi nition focus on  population health (Meier  2006 ). In addition, 
the proliferation of non-state actors in  global health mentioned earlier (e.g., relief 
agencies, academic health partnerships, corporations, philanthropies) make  coordi-
nation and  accountability about the right to health more demanding. By and large, 
governments are the sole entities authorized to sign health-related  human rights 
treaties such as the  ICESCR . International treaties typically have mechanisms for 
ensuring that signatories fulfi ll legal commitments. But as discussed earlier, the 
diminishing role of governments in national  policy and the increasing privatization 
of public services under  globalization (WHO  2002 ) mean that treaty  law will likely 
play a correspondingly smaller role in  global health  collaboration . Although the 
infl ux of new non-state actors allows  stakeholders to partner in innovative ways to 
address challenges in global health, the stability and accountability of international 
 human rights law remains a valuable asset in a constantly evolving fi eld. 
 Most  cases in this chapter feature ethical issues that are illuminated but some-
times complicated by the  human rights framework. In Jensen and Gaie’s case, 
human rights potentially impede a public health strategy for controlling the spread 
of  HIV/AIDS . The case calls for a public health offi cial to balance the human rights 
9  Until 2006, the U.N. Commission on Human Rights. 
10  The Human Rights Council also uses working groups. 
11  For special procedures of the Human Rights Council, see  http://www.ohchr.org/EN/HRBodies/
SP/Pages/Welcomepage.aspx 
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of individuals (possibly suffering  discrimination and stigma-related violence under 
routine or mandatory testing  policies ) against the health of the community, which, 
arguably, is better served by precisely such testing regimes. 
 A distinguishing mark of  globalization is the increased infl uence of transnational 
businesses on the policies of  LMIC  governments . Timms’ case illustrates the impact 
of this  development . Given the economic and  political clout of transnational busi-
nesses, there are continuing discussions on the extent of their  human rights  obliga-
tions (Weissbrodt and Kruger  2003 ; Ratner  2001 ). In this case, even if the 
pharmaceutical  company conducting  research in  India is not directly bound by a 
 human rights treaty, is it obliged to comply with human rights  norms on some other 
basis (e.g., national  laws , industry  standards , corporate codes of conduct)? 
 In 2011, the  U.N. Human Rights Council endorsed the  Guiding Principles on 
Business and Human Rights , a document outlining what has come to be known as 
the U.N. “Protect, Respect and Remedy” framework.  Guiding Principles recognizes 
governments’  duty to  protect human rights, acknowledges corporate responsibility 
to  respect  human rights , and requires  governments to ensure that people  harmed 
within their jurisdiction have access to effective judicial and nonjudicial  remedies . 
 List and Boyd’s case questions how one’s  freedom of expression (Article 19, 
 ICCPR ) affects public health. Should one be allowed to use the free press to advo-
cate on behalf of fellow citizens? Does the free press furnish a forum for an informed 
and representative discussion on  public health policy ? Are expatriate workers less 
likely than nationals to face offi cial retaliation when they use media outlets to criti-
cize  government ? 
 Confl ict in the Balkans and killings in Rwanda in the early 1990s revived lively 
debate on the international community’s  obligation to intervene in internal affairs of 
member countries to defend  human rights (Kardaş  2010 ; Chopra and Weiss  1992 ). 
Organizing international action to address human rights  violations remains a peren-
nial challenge—exemplifi ed by the intractable situation in  Syria following major 
pro-democracy protests in 2011. But ideological alliances and rivalries during the 
 Cold War made consensus building around such interventions arduous (Eisner 
 1993 ). The Balkan and Rwandan  confl icts and a growing atmosphere of  cooperation 
 in the face of global challenges (e.g., environmental degradation,  climate change ) 
contributed to an increase in peacekeeping and humanitarian operations organized 
by the international community. These operations, though designed to further 
 human rights , sometimes undermined the target  population’s  right to health . 
 Millum’s case and that of Al-Faisal, Hussain, and Sen raise issues that result, 
paradoxically, from increasing adoption of the  human rights framework as an inter-
national  norm . Millum’s case questions responsibility during a major cholera out-
break originating in a camp occupied by Nepali soldiers on a U.N. peacekeeping 
mission in the Caribbean. The Al-Faisal, Hussain, and Sen case considers how the 
health of vulnerable groups in  Iraq and  Syria is affected by economic  sanctions 
imposed on the two countries’  governments and shows how interventions intended 
to protect  human rights can still have adverse health consequences. 
 Increasingly, human rights are being used to frame responses to  global public health 
challenges (Adorno  2009 ; Mann  1997 ).  Human rights are a pervasive transcultural and 
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normative discourse. Issues once relegated to  bioethics are now cast as human rights 
concerns (Adorno  2009 ; Faunce  2005 ). For example, UNESCO adopted three declara-
tions that use human rights to frame health challenges: the  Universal Declaration on 
the Human Genome and Human Rights ( 1997 ), the  International Declaration on 
Human Genetic Data ( 2003 ), and the  Universal Declaration on Bioethics and Human 
Rights ( 2005 ). Each declaration codifi es the  principle of  informed consent —a princi-
ple at stake in the case cited by Lee, Kleinfeld, and Glassford and, to a lesser degree, 
the case by Timms. The cross- fertilization of concepts and concerns between bioethics 
and  human rights is a salutary consequence of public health partnerships forged in an 
increasingly interconnected and complex world. 
8.3.3  Social Determinants of Health 
 The social determinants of health (SDH) framework is based on  social justice (Lee 
 2004 ). The guiding  principle of SDH is  equity. As with public health, SDH empha-
sizes  population  health  and  prevention . However, SDH goes beyond traditional pub-
lic health approaches because, in addition to deploying interventions aimed at 
reducing population mortality and morbidity, SDH targets “the social context and 
conditions in which people live” (Blas et al.  2011 ). These contextual factors and 
conditions that affect  health outcomes in a given  population are called  social deter-
minants of health . 12 These include such factors as housing, education, transporta-
tion, employment, insurance coverage, and access to health care (Brennan Ramirez 
et al.  2008 ). 
 The SDH framework stands on 40 years of  research demonstrating that clinical 
care alone cannot improve  health outcomes unless social factors are addressed 
(WHO  2007 ). Statistical associations between social disadvantage and poor health 
became increasingly clear, impelling the inference that closing the gap in health 
status between populations required corresponding improvements in the social con-
texts of disadvantaged populations. 
 The ethical  norm underlying efforts to eliminate these preventable health differ-
ences is the  principle of  equity .  Health  in equities are differences “socially produced; 
systematic in their distribution across the  population ; and unfair” (WHO  2007 ). On 
the other hand,  health  equity is “the absence of unfair and avoidable or remediable 
differences in health among population groups defi ned socially, economically, 
demographically, or geographically” (WHO  2007 ). These defi nitions highlight two 
aspects of SDH. First, the differences in health are not merely descriptive but pre-
scriptive as well, implying an ethical  obligation in favor of their elimination. Second, 
the focus on social context and conditions means that  policy and action must be 
 intersectoral , involving actors and spheres outside the health fi eld (WHO  2007 ). 
12  The social determinants of health have also been characterized as “the conditions in which peo-
ple live and work that affect their opportunities to lead healthy lives” (Labonté and Schrecker 
 2007 ). 
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 Health  disparities among  populations in different parts of the world motivate 
public  health interventions and assist the development of useful analytical tools for 
global health.  A case in point would be the gaps in  infant mortality rates and life 
 expectancy between countries with strong economies and  LMICs . These gaps pro-
vide moral stimulus for elimination and benchmarks for setting goals and assessing 
progress (e.g., the health-related  Millennium Development Goals ). 
 The SDH framework faces several challenges and limitations. Most people do 
not realize the impact of social and contextual factors on  health outcomes .  Political 
orientations and worldviews further impede the acceptance of SDH as a viable  pol-
icy alternative (Gollust et al.  2009 ). Some argue that variations of SDH oversimplify 
the link between wealth and health, thereby failing to consider other causes of  health 
disparities (Poland et al.  1998 ). Even though statistical links have been made 
between social context and ill health, scientifi c questions remain on the mechanisms 
that account for these associations. This is especially critical in the fi eld of  mental 
health , where attempts have been made to clarify associations between SDH and 
psychological well-being (Marmot et al.  1997 ; Bovier et al.  2004 ; Fisher and Baum 
 2010 ; Paananen et al.  2013 ). 
 Aside from the availability of  HIV/AIDS health services and  medication , the 
Jensen and Gaie case and Zinner case demonstrate how social factors affect health. 
In Jensen and Gaie, advocates of client-initiated  voluntary testing (vigilant, rights- 
based) offer compelling reasons to minimize the potential for  discrimination and 
stigma-related violence against people living with  HIV . As the case points out, the 
 risk of violence or discrimination is particularly high in  LMIC societies where 
social, cultural, and legal protections are nonexistent or being developed. 
 Although HIV-positive status can have adverse social consequences, Zinner illus-
trates how social factors increase the risk of infection in the fi rst place. In this case, an 
international anti-AIDS program administering pre-exposure prophylactic  medica-
tion is deciding whether to budget small sums of money to educate young girls in the 
community. Investing in education should reduce their likelihood of getting infected 
in unequal liaisons with  older men (sugar-daddy relationships) while creating open-
ings in the program for other at-risk groups to participate. In effect, the program is 
considering medical intervention (i.e., a pre-exposure prophylactic drug) and social 
determinants of health (i.e., girl–child education) in making its  allocation decisions. 
 Both Timms’ and Lee, Kleinfeld, and Glassford’s cases show how  social deter-
minants (e.g., gender, caste, economic status, literacy) infl uence the  effectiveness of 
 informed consent for vulnerable  LMIC  populations participating in drug  research . 
Less direct but equally critical, these cases also show how geographic disparities in 
 social conditions establish context for  global health research. The challenge of 
ensuring that drug research is conducted ethically in LMICs derives from such con-
textual factors as greater  disease burdens in these regions due to underdeveloped 
health systems, lax  regulation of  biomedical research due to ineffective governance 
structures, and economic and social  vulnerability of most potential research partici-
pants (Barlett and Steele  2011 ). 
 In the context of SDH,  empowerment “is inseparably linked to marginalized and 
dominated communities gaining effective control over the  political and economic 
processes that affect their well-being” (WHO  2007 ). List and Boyd’s case demon-
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strates how citizens of  LMICs can use mass media to infl uence their  governments 
on public health topics. A physician-national in an East African country fears retali-
ation if she talks to the media about a TB medication  stock-out potentially due to 
government corruption and misuse of public funds. Her fears underscore the  risks 
and responsibilities associated with the role of health workers as advocates for the 
socially and politically marginalized in their communities (Pérez and Martinez 
 2008 ; Farmer  2004 ; Geiger and Cook-Deegan  1993 ). Also pertinent from a global 
SDH perspective is the  likelihood that an expatriate whistleblower, especially a citi-
zen from a higher-income country, would not face as serious a risk. 
8.4  Summary 
 The approaches and methods for collaborating in  global public health are diverse—
just like the cases in this chapter. These cases refl ect the rich and multifaceted con-
text for global public health while also emphasizing the role that different ethical 
 standards (and the foundations for those standards) play. In so doing, the cases offer 
a fresh and innovative perspective on the ethics of public health. 
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8.5  Case 1: The Ethics of HIV Testing  Policies 
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 This case is presented for instructional purposes only. The ideas and opinions 
expressed are the authors’ own. The case is not meant to refl ect the offi cial position, 
views, or policies of the editors, the editors’ host institutions, or the authors’ host 
institutions. 
8.5.1  Background 
 The  global public health community has signifi cantly advanced our understanding 
of the biology of the human immunodefi ciency virus ( HIV ) and developed reliable 
diagnostic tests and effective antiretroviral  treatments . Despite these advancements, 
the rate of prevalence and transmission, especially in low- and middle-income  coun-
tries , remains alarmingly high.  HIV prevention , often considered better than a cure, 
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remains the mainstay of our collective response to the epidemic. By all accounts, 
 HIV testing plays a pivotal role in treatment and  prevention , yet in low- or middle- 
income countries, only 10 % of those who have been exposed to HIV infection may 
have access to  counseling and testing (UNAIDS/WHO  2004 ; Centers for Disease 
Control and Prevention  2012 ) . In general, HIV testing policies range from  voluntary 
or client-initiated counseling and testing to provider-initiated approaches (e.g., rou-
tine testing, mandatory HIV  screening ). Most  policy makers and health workers 
have promoted voluntary HIV testing, although routine HIV counseling and testing 
increasingly is being adopted. Notably, however, the  global health community has 
adamantly discouraged mandatory  HIV testing (UNAIDS/WHO  2004 ). 
 Resource-poor countries may be unable or unwilling to ensure social and medical 
infrastructures adequate for safeguarding the  human rights of people seeking ser-
vices. As a result,  global health offi cials have encouraged countries to adopt  volun-
tary or client-initiated  counseling and testing policies opposed to routine or 
provider-initiated policies. Even in settings in which voluntary counseling and testing 
is readily available, few people take advantage of these services. Stigmatization per-
sists as an obstacle to  HIV counseling and testing, which, by all accounts, is vital to 
effectively treat people living with HIV and  AIDS and to reduce further infection. 
 Many public health ethicists recommend that  policy makers and health workers 
carefully consider the ethical consequences of routine testing policies, especially 
for people in locales that lack protections against  discrimination and stigma-related 
violence (Rennie and Behets  2006 ). To protect individuals against HIV-related dis-
crimination and threat of violence, advocates of the human-rights approach vigi-
lantly oppose the application of  standard methods of disease control, which include 
mandatory testing and partner notifi cation. But this vigilant rights-based approach 
to  HIV prevention , an approach that Bayer ( 1991 ) labelled  AIDS exceptionalism , 
can undermine society’s ability and indeed responsibility to control the epidemic. 
And although public health offi cials are a minority, some argue for mandatory  HIV 
testing (Schuklenk and Kleinsmidt  2007 ), seeing it as the only way to control the 
 HIV epidemic. Failure to apply standard methods of disease control, some argue, 
devalues public health and  social justice (Frieden et al.  2005 ; De Cock et al.  2002 ). 
By treating  HIV/AIDS differently than other  infectious diseases , AIDS exceptional-
ism may inadvertently increase stigmatization rather than reduce it (De Cock et al. 
 2002 ). Proponents of testing point to its potential to reduce stigma by raising aware-
ness, preventing transmission, expanding  treatment , and empowering individuals 
(Crepaz et al.  2004 ). 
 HIV testing policy recommendations from the global international public health 
community can also challenge if not undermine the authority of the indigenous 
knowledge system or indigenous ethical codes (Chilisa  2005 ; Dube  2006 ; Jensen 
and Gaie  2010 ). These recommendations  typically stipulate ethical preconditions 
within  voluntary HIV testing  policies , such as strict confi dentiality,  informed con-
sent , and competent pre- and post-test counseling. Some argue that preconditions 
constitute a  Western approach that blocks local efforts to control the epidemic. 
Although many believe that the context of provider-initiated  HIV testing preserves 
“suffi cient voluntariness,” others have criticized this approach. Critics maintain 
that opting-out from provider-initiated HIV testing differs signifi cantly from 
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 client- initiated or voluntary HIV  counseling and testing (Kenyon  2005 ). In either 
case, all agree, medical practitioners and  policy makers cannot guarantee ideal or 
even adequate social and institutional support services (Weiser et al.  2006 ). 
 These disputes are by no means merely theoretical. In Botswana, for example, 
policy has shifted within the past 5 years from a client-initiated to a provider- 
initiated or routine  HIV diagnostic counseling and testing strategy (Botswana 
Ministry of Health  2012 ). More recently, in response to a parliamentary-approved 
public health bill presently being contested as unconstitutional (Botswana Network 
on Ethics, Law and HIV/AIDS  2012 ), the debate has shifted to whether certain 
conditions render mandatory testing ethically permissible. 
8.5.2  Case Description 
 The Minister of Health of a sub-Saharan nation has asked you, a public health offi cial 
and physician from a  Western country, to recommend an effective  HIV testing policy . 
The sub-Saharan nation is among the hardest hit by the  HIV epidemic (e.g., the HIV 
prevalence rate among pregnant women aged 15–49 is >25 %). In this resource-poor 
nation, people with HIV and  AIDS are commonly stigmatized despite national cam-
paigns to reduce stigma. Even if the nation were to adopt a  policy of  voluntary HIV 
counseling and  testing , more than 50 % of people living with HIV and  AIDS are unaware 
of their serostatus. Although  HIV  treatment is currently unavailable, international donors 
have promised to provide free or inexpensive  antiretroviral therapies (ART) . 
 You have sought the input of your colleagues in  global public health only to dis-
cover they are contentiously divided. Some vigorously oppose enhanced HIV test-
ing  policies that would move from voluntary to routine  HIV testing to protect the 
community against  discrimination or stigma-related violence. They also oppose in 
 principle Western-based interventions, which, they say, undermine traditional loci 
of authority and indigenous systems of medical knowledge. Other colleagues insist 
that human rights-based approaches undermine public health’s ability, as well as 
responsibility, to control the  HIV epidemic. They are for moving beyond client- 
initiated approaches and vigorously support mandatory  HIV testing . These 
 colleagues feel that the only way to control the HIV epidemic is to apply the  stan-
dard methods of disease control. 
 Given these divergent views, you hope to be able to recommend a  HIV  policy 
that strikes a balance between the Hippocratic ideal of doing no harm and the 
equally compelling mandate to protect if not improve public health. 
8.5.3  Discussion Questions 
 1.  How might an emphasis on protecting  human rights in  HIV prevention reduce 
the importance of public health and social justice? 
 2.  Is opting in, or not opting out, as part of the routine testing strategy, ethically 
equivalent to acquiring  consent within a  voluntary testing site? What are the 
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necessary and suffi cient conditions, ethical or otherwise, for “adequate  informa-
tion ” or “suffi cient voluntariness” in cases of  HIV testing ? 
 3.  Is there an ethical  confl ict between one’s duty, whether as a physician or a public 
health offi cial, whether as the minister of health or simply as a person, to adopt 
what are considered to be effective methods of controlling disease, e.g.,  HIV , and 
the  obligation to  respect indigenous knowledge systems and approaches to pub-
lic health? If there is a confl ict, which duty should take  precedent ? 
 4.  What  policy would you recommend under these circumstances? And what ethi-
cal  principles guided your recommendation? 
 5.  How would your recommendation provide, if at all, protections against discrimi-
nation and stigma-related violence? 
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8.6  Case 2: Just  Allocation of Pre-exposure Prophylaxis 
Drugs in  Sub-Saharan Africa 
 Susan  Zinner 
 School of Public and Environmental Affairs 
 Indiana University Northwest 
 Gary ,  IN ,  USA 
 e-mail: szinner@iun.edu 
 This case is presented for instructional purposes only. The ideas and opinions 
expressed are the author’s own. The case is not meant to refl ect the offi cial position, 
views, or  policies  of the editors, the editors’ host institutions, or the author’s host 
institutions . 
8.6.1  Background 
 During the summer of 2012, the  U.S. Food and Drug Administration (FDA) 
announced the approval of  Truvada (emtricitabine/tenofovir disoproxil fumerate) 
for use in  pre-exposure prophylaxis programs (PrEP) for people at high  risk of  HIV 
infection (FDA  2012 ). After successful use of  antiretroviral therapy (ART) drugs to 
treat HIV/AIDS-infected  populations , researchers found that daily prophylactic use 
of these drugs in uninfected individuals who engaged in high-risk activities was also 
effective in reducing their risk of  HIV/AIDS . The U.S.  Centers for Disease Control 
and Prevention (CDC) noted that PrEP could reduce  HIV rates for men having sex 
with men if those at high risk of  HIV infection were targeted and if PrEP was used 
as part of a comprehensive set of preventive services, including regular monitoring 
of HIV status, adherence, and risk behaviors (CDC  2011 ). Candidates for Truvada 
should fi rst be tested for HIV to ensure that they are in fact HIV negative before 
beginning the  PrEP program. 
 This innovative prophylactic approach to reducing the likelihood of contracting 
 HIV holds great promise. One study found that Truvada reduced the  risk of  HIV 
infection 42 % compared with men taking placebos and having sex with other men 
(Grant et al.  2010 ), whereas a second study found that risk fell by up to 75 % com-
pared with  serodiscordant couples taking placebos (Baeten et al.  2012 ). However, 
Truvada is associated with some side effects, including nausea and  vomiting  (CDC 
 2011 ) and possible decreases in bone mineral density (Grigsby et al.  2010 ). 
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Furthermore,  Truvada is contraindicated for anyone with decreased kidney  function. 
Regular testing of kidney function is recommended for those people taking this 
 medication (CDC  2011 ). 
 Truvada has been tested only in  serodiscordant couples —not in women. Its effi -
cacy in the general  population of women, in sex workers, and in young girls in 
sugar-daddy relationships (i.e., young girls in unequal relationships with older 
males) is unknown. 
 Sub-Saharan Africa has been hit especially hard by HIV/ AIDS . An estimated 
two-thirds of people affected by  HIV worldwide are concentrated in this area, 
although signifi cant variations exist in different parts of the continent (Kalipeni 
et al.  2004 ). Unfortunately, the distribution and availability of  ART drugs have 
exposed the inadequacies of some African national health systems, such as the neg-
ative effects of a long-neglected health sector, economic challenges, declining pub-
lic expenditures, and decentralized funding (Schneider et al.  2006 ). 
 Many international aid groups help fund public health programs, including pro-
grams to reduce the spread of  HIV/AIDS . Programs such as PEPFAR (The  United 
States President’s Emergency Plan for AIDS Relief) , the  Global Fund , the  World 
Bank , the United  Nations , and the  Gates Foundation have all contributed large sums 
of money for this purpose. 
 African groups at high  risk of contracting new infections (and thus good poten-
tial candidates for  PrEP ) include sex workers, men having sex with men,  serodiscor-
dant couples , and girls in sexual sugar-daddy relationships. The latter group poses 
specifi c ethical issues. These girls, typically teenagers, may be coerced into sexual 
relationships with men old enough to be their fathers or even grandfathers through 
the offering of gifts or money. These sugar daddies generally engage in multiple 
sexual relationships, possibly with a spouse and several young women, while put-
ting the girls at risk of  HIV . Every averted case of HIV increases economic produc-
tivity, lowers the risk of social unrest, strengthens the labor force, and improves the 
investment climate (Over  2011 ). 
8.6.2  Case Description 
 You are the head of an international anti-AIDS effort currently stationed in a com-
munity of 40,000 in sub-Saharan Africa, where the  HIV prevalence rate is 21 %. You 
have received funding from different world organizations, including some based in the 
 United States . Your organization is piloting the use of  Truvada in  populations that are 
at high  risk of  HIV . The organizations funding this project will allow you and the two 
health workers assigned to assist you to make all  allocation decisions. 
 The  cost of Truvada for one patient is about $500 per year. Those living in this 
community are poor, and none could afford this drug without the existence of your 
program. Many populations in the community are at high risk of  HIV infection , 
including homosexual and bisexual men who routinely engage in sex with other 
men, girls in sugar-daddy relationships, sex workers, and  serodiscordant couples . 
You have been given enough  Truvada to treat and monitor 100 patients for a year. 
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The funding organizations have indicated that they are likely to provide more 
Truvada if you fi nd its use results in no or few new infections during the year among 
the 100 selected patients. The community of 40,000 people include the following:
•  80 men who have sex with other  men ; 
•  80 girls in sugar-daddy relationships; 
•  40 sex workers; and 
•  30  serodiscordant couples (60 people; noninfected partner receives  Truvada 
while the infected partner is not medically eligible for  ART ). 
 One challenge you face is that many feminist organizations and  child health advo-
cates are pressuring you to include all girls in the group because ample  research shows 
that girls in sugar-daddy relationships are relatively powerless and cannot ask their 
partners to wear a condom, virtually ensuring that these girls will become infected. 
There is some evidence, however, that simply paying girls a small amount of money 
to attend  school (and thus dramatically reducing the possibility of these relationships) 
is cost effective. If you adopt this approach, you could use the  Truvada for the other 
groups. You may need to consider whether to request more money from the funding 
organizations if you adopt this approach. One of your organization’s goals is to  respect 
cultural  norms and beliefs if the health of those at  risk of  HIV/AIDS is not jeopar-
dized. You have been asked to allocate the  PrEP drugs in your community. 
8.6.3  Discussion Questions 
 1.  What role should the community play as you make your  allocation decisions? 
How do you remain culturally sensitive when implementing this program? 
 2.  Create a rubric to help you consider each group for  inclusion in the PrEP pro-
gram. What factors will you weigh in making  allocation decisions? If you do not 
pick an entire group, what criteria do you use to select individuals in that group? 
How would your criteria differ if you were distributing  ART drugs to infected 
individuals (and not to those who are at risk but not infected)? 
 3.  What role should the likelihood of patient adherence play in your  allocation 
decision? Keep in mind that patients are expected to take their  medication daily 
on a strict time schedule. 
 4.  How will you determine if your program is successful? How will you determine 
whether your  allocation decisions are just and fair? 
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8.7  Case 3:  Drug Trials in Developing Countries 
 Olinda  Timms 
 Department of Health and Humanities 
 St. Johns Research Institute 
 Bangalore ,  Karnataka ,  India 
 e-mail: olindatimms@gmail.com 
 This case is presented for instructional purposes only. The ideas and opinions 
expressed are the author’s own. The case is not meant to refl ect the offi cial position, 
views, or  policies  of the editors, the editors’ host institutions, or the author’s host 
institutions . 
8.7.1  Background 
 Clinical trials outsourced to  India offer, in addition to business opportunities for 
clinical  research management, the prospect of health infrastructure development 
and collaborative  research . Since 2005, drug trials in India have increased as foreign 
drug companies eagerly take advantage of the favorable research environment 
(British Broadcasting Corporation [BBC] News  2006 ; Russia Today  2010 ; Overdorf 
 2011 ; John  2012 ). These advantages include highly qualifi ed English-speaking 
doctors, a large and diverse  population , and lower  costs and relative  freedom from 
burdensome  regulations for privately funded research  trials  (World Health 
Organization  2008 ). As a result, clinical research organizations working on behalf 
of  pharmaceutical companies frequently approach doctors in private or  government 
practice to recruit patients for drug trials, often offering attractive payouts per recruit 
and promising coauthorship and publication credits as incentives. 
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 For vast sections of its demographic,  India grapples with inadequate access to 
health services and high rates of  infant mortality and communicable diseases 
(Government of India Planning Commission  2011 ). Only a small slice of the  popu-
lation can afford the high-end private and corporate hospital care in urban pockets 
of the nation. Though extremely deferent to physicians, the Indian population is 
insuffi ciently informed about the  risks and benefi ts of  clinical trials . Illiterate, 
impoverished, and unaware of the implications of  participation , many drug trial 
recruits are vulnerable to exploitation (Srinivasan and Nikarge  2009 ). With limited 
health care options, some gladly enroll in a drug trial, considering themselves fortu-
nate to receive medical attention, food, and  compensation for local travel. Such 
circumstances compromise the intent behind freely giving  informed consent . 
 The media has drawn attention to several high-profi le cases. These involved poor 
people from lower castes who enrolled in drug trials without adequate  consent , 
resulting in severe adverse effects, including death (Lloyd-Roberts  2012 ). Citing 
data for 2005–2012, the BBC reported that 2,000 clinical trials took place in  India . 
The death count among people enrolled in these  clinical trials was 288 in 2008, 
637 in 2009, 668 in 2010, and 438 in 2011 (Lloyd-Roberts  2012 ). The media also 
raised concerns about inadequate  regulation of private trials, inconsistent applica-
tion of  informed consent requirements, and irregularities in ethics reviews (The 
Hindu  2011 ; The Indian Express  2012 ). 
 Although offi cials have been responsive to these concerns, their efforts still leave 
the vulnerable unprotected. In 2000, the Ministry of Health and Family Welfare 
established legal  guidelines regulating the conduct of  research in  India that align 
with international guidelines on  research ethics including the  International 
Conference on Harmonisation of Good Clinical Practice (ICH-GCP) ( 1996 ), the 
 Declaration of Helsinki (World Medical Association  2008 ) and  Council for 
International Organizations of Medical Sciences (CIOMS) guidelines ( 2002 ). The 
 Indian Council of Medical Research also developed guidelines specifi cally for  clini-
cal trials ( 2006 ). Further, the Drugs and Cosmetics Rules were amended to require 
review and registration of trials and to compensate trial participants or their families 
in the event of an  adverse event (Government of India  2005 ) . Unfortunately, adverse 
events go grossly underreported. Few recruits receive compensation, and hardly any 
investigations result in convictions for unethical  research practices . 
8.7.2  Case Description 
 Sharada, a 45-year-old woman of  a  low social caste in an impoverished town in  India , 
lives on less than 2 U.S. dollars a day. She has access only to the  government hospi-
tal system that provides free health care to underserved citizens. Complaining of 
chest pains, she is taken to the nearest government hospital and diagnosed with heart 
and renal failure. Pharmakon, a  multinational pharmaceutical  company , happens to 
be conducting a trial for a drug that has renal-protective effects in cardiac failure. 
From a colleague serving as a site investigator for this trial, Sharada’s cardiologist 
hears that pilot testing of the drug has shown promising results. But he also learns that 
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his colleague’s  compensation is tied to the number of subjects he enrolls in the study. 
Worse, Pharmakon has a history of enrolling patients without ensuring they fully 
understand they will be participating in a  research project . Despite misgivings about 
this history and his colleague’s fi nancial incentive to enroll patients, Sharada’s cardi-
ologist recommends that she enroll in the drug trial. He emphasizes that enrollment 
offers the only way to obtain an expensive drug necessary to save her life that would 
otherwise be unaffordable. Given the family’s lack of education, he is uncertain how 
much they understood, yet they seem grateful for the prospect of immediate care and 
 treatment . While on this  medication , Sharada develops cardiac arrhythmias, is taken 
off the drug, and is discharged from the hospital in a few days. Almost a month later, 
she succumbs to cardiac arrest at home. Soon thereafter, the high number of serious 
drug-related complications forces discontinuation of the drug trial. 
8.7.3  Discussion Questions 
 1.  Who are the  stakeholders in this case, what is at stake for each of them, and what 
 values does each bring to the situation? 
 2.  What are the  risks and benefi ts of enrolling impoverished, uneducated patients 
living in developing countries in clinical drug trials? What are the barriers to 
obtaining true  informed consent from these patients, and what can be done to 
overcome these barriers? 
 3.  What are  the ethical implications of tying a researcher’s  compensation to the 
number of subjects enrolled? Should this practice be permitted? 
 4.  Are  multinational  pharmaceutical companies that benefi t from cost-effective 
drug trials in developing countries obligated to improve the lives of people living 
in those countries? 
 5.  Who should be held responsible for  adverse events due to a drug trial conducted 
by a  multinational company in a country where there is limited health insurance, 
no social security, and poor enforcement of  regulations ? What international or 
grassroots efforts might help ensure  accountability for adverse events? 
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 This case is presented for instructional purposes only. The ideas and opinions 
expressed are the authors’ own. The case is not meant to refl ect the offi cial position, 
views, or  policies  of the editors, the editors’ host institutions, or the authors’ host 
institutions . 
8.8.1  Background 
 The  World Health Organization (WHO) maintains  a  list, updated every 2 years, of 
medications it considers essential—medications that a given country should have on 
hand to distribute to its citizens (WHO  2015 ). In functioning health systems, the 
intent is to have essential medicines of assured quality available at all times in ade-
quate amounts, in appropriate dosage forms, and at an affordable price (WHO 
 2015 ). Among those medications are treatments for tuberculosis (TB), a ubiquitous, 
slow-growing bacteria that kills 1.4 million people annually (WHO  2012 ). 
 Control of TB requires the availability of medication for months of  treatment . 
Procurement of  TB medication requires an intact and predictable supply chain. 
Ideally, ministries of health in low-income countries forecast accurately the number 
and types of medications needed to treat the local burdens of disease. Then  govern-
ments typically purchase medications to store in a central facility for regional distri-
bution. Ineffi ciencies in  drug supply forecasting; stocking practices;  storage 
capabilities; transportation capacity; and timely funding, procurement, and delivery 
can lead to a breakdown in a supply chain. 
 One barrier to TB control in low-resource countries, as well as in the  United 
States , is intermittent unavailability of  TB medication , an occurrence known as a 
stock- out  (Centers for Disease Control and Prevention  2013 ). Medication stock- 
outs often result in delayed  treatment , an increased  risk of  drug resistance in incom-
pletely treated people, and the potential for untreated or incompletely treated people 
to infect others. Stock-outs occur for different reasons, including budget constraints, 
poor drug procurement  policies and distribution networks, and  political corruption 
slowing drug availability (Stop Stock-outs Campaign  2010 ). 
 Although 80 % of national  ministrie s of health reporting to WHO have an unin-
terrupted supply of fi rst-line TB medications, 45 % of the 20 highest-burden coun-
tries report stock-outs (WHO  2009 ). More recently, 14 countries experienced 
anti-TB drug stock-outs in 2011 (Stop TB Partnership  2011 ). To contend with 
 recurrent stock-outs, the Stop TB Partnership provides technical support and drug 
procurement avenues to resource-poor nations through its Global Drug Facility 
(GDF) and Green Light Committee (GLC) (Stop TB Partnership  2011 ). Although 
GDF and GLC are essential players in ensuring at-risk nations have adequate  drug 
supplies , both are limited in how quickly they can respond to stock-outs. 
 Advocacy groups and nongovernmental  organizations can generate widespread 
public attention in hope of quicker resolution of stock-outs. A paucity of literature 
covers the ethical roles of expatriate health workers in stock-outs. The  model of 
“ethics of engaged presence” in health practice for expatriate health workers in low- 
income countries may offer a framework of  solidarity with local people (Hunt et al. 
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 2012 ). This nondirective framework broadly centers on the moral dimensions of 
expatriate involvement in humanitarian health work undertaken with local individu-
als. Still, limited ethical  guidelines exist for expatriates who seek to enter foreign 
 political and social forays to affect change—leaving the problem of essential  TB 
medication stocks-outs unresolved. 
8.8.2  Case Description 
 You are a visiting researcher in an East African country investigating TB case- fi nding 
detection strategies in an urban area. This country has one of the highest TB burdens 
in the world. Its  government funds the national medical stores to stock anti- TB drugs 
per WHO’s essential  medication list. On occasion, you work in the TB clinic at the 
local hospital treating TB patients, some of whom have multidrug- resistant  TB . You 
know that your research  participants are guaranteed TB drugs through your study’s 
funding. Potential participants who do not qualify for the study but have active TB 
infection are referred to a local clinic. 
 After months living and working  i n this country, you learn that many of the urban 
and rural clinics carry an inadequate supply of anti-TB medications. You speak with 
local doctors about the anti-TB drug shortage. They are frustrated and speculate as 
to why there have been stock-outs. Some suspect corruption and misuse of funds by 
the ministries of fi nance and health are to blame. Others blame drug manufacturers 
for unreliable supplies. 
 You search for drug stock-outs in this country using Internet search engines and 
come across stock-outs for other drugs but fi nd no mention of anti-TB drug stock- 
outs. You return to a weekly clinic meeting and note that the news has not covered 
the stock-outs your colleagues are experiencing at their clinics. You ask if any of 
them will push the ministry of health to fi x the shortage. One physician says he 
heard that the ministry will “provide the TB drugs again shortly.” You suggest that 
one of the physicians contact someone from a media outlet to raise attention. After 
a period of silence, a physician says she fears that the  government will somehow 
retaliate if this issue is raised. 
 After further conversations with colleagues, you decide to attract media attention 
to this issue. Your local colleagues support you, even saying they will provide you 
with data about the stock-out. Contacts in your U.S.-based sponsoring organization 
feel ambivalent about your working with the media to raise attention but will not 
prohibit it so long as you do not mention your affi liation. 
 You decide to contact an international health and  human rights organization about 
the stock-out, and its staff puts you in touch with a local partner organization. The 
local partner wants you to speak, along with local human rights advocates, at a stock-
out conference and interview with newspaper reporters. Despite your wanting to help 
those dependent on the national  drug supply for their TB  treatment , you are  confl icted 
about your  participation and its possible repercussions. Before committing, you tell 
the local partner that you need to think the matter through thoroughly. 
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8.8.3  Discussion Questions 
 1.  What are some  risks and benefi ts of your involvement with the stock-out confer-
ence and contact with the media?  What ethical concepts should inform your 
decision? Would your decision change if your colleagues or sponsoring organi-
zation urged you to say nothing? 
 2.  How does your limited understanding of local institutional hierarchy and gover-
nance inform your ethical analysis of whether or not to engage in  advocacy 
around stock-outs? If you conclude you should engage, are there ways to do so 
besides public testimony? 
 3.  Does it matter ethically if the stock-out pertained to antimalarial medications; that 
is, a  medication outside your  research area ( TB medication )? Why or why not? 
 4.  In terms of perceptions and consequences from the media and  government min-
istries, how might your public reporting of the stock-out differ from a local offi -
cial reporting it? What different types of impact might result from each? How 
might your ability to work with local health  professionals in the future be affected 
if you report the alleged stock-out? 
 5.  Knowing that you have ready access to anti-TB medication for research partici-
pants, should you broaden the  inclusion criteria to allow more patients to receive 
guaranteed  treatment ? Why or why not? 
 6.  Should you attempt to bring the stock-out to the attention of the  global health 
international community by inviting members of the international media to the 
stock-out conference? If not, why not? If so, what approaches might interna-
tional and local nongovernmental  organizations , World Health  Organization 
departments, and patient advocacy groups employ to effectively publicize and 
resolve stock-outs? If not, why not? 
 7.  Do you have an ethical  duty  to report the stock-out if local health offi cers will not 
do so? 
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8.9.1  Background 
 Cholera is caused by infection with  Vibrio cholerae bacteria, which colonize the 
small intestine and produce cholera toxin. The disease is characterized by sudden 
onset of severe, watery diarrhea and vomiting. Left untreated, cholera rapidly leads 
to dehydration and shock. Severe cholera can be fatal in more than 50 % of cases. 
Prompt  treatment  reduce s the case fatality rate to less than 1 % (Boore et al.  2008 ). 
Treatment primarily addresses the loss of fl uids: patients should be aggressively 
treated with oral rehydration solution or, if severely dehydrated, through intrave-
nous fl uids. Treatment with  antibiotics shortens the course of the disease. 
 Cholera is transmitted through contaminated food or water. In developing coun-
tries, where most infections and deaths occur, inadequate  sanitation is frequently the 
cause of the spread of  V. cholerae , as untreated fecal matter from cholera sufferers 
leaks into the water supply. Each year, 3–5 million cases of cholera occur, leading 
to about 120,000 deaths (Harris et al.  2012 ). 
 Cholera is endemic in more than 50 countries. In many places, cholera outbreaks 
are seasonal—fl aring up during the rainy season and dying down again during dry 
periods. Outbreaks can be prevented or contained by properly treating sewage, pro-
moting rigorous hygiene practices, and sterilizing drinking water. Two oral cholera 
 vaccines are commercially available but not included in most cholera control 
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 programs, although the  World Health Organization (WHO) recommends them for 
use in outbreaks and for high-risk populations (WHO  2010 ). Before 2010,  Haiti had 
not experienced cholera for at least a century. 
 Haiti , a country of ten million people, occupies the  western portion of the island 
of Hispaniola in the Caribbean. Although its per capita gross domestic product 
(GDP) is about $1,200 (Central Intelligence Agency  2012 ), 13 a tiny elite controls 
most of the country’s wealth. With 80 % of the  population living below the poverty 
line, Haiti is the lowest-ranked country in the Americas on the  United Nations 
(U.N.) Human Development Index (UNDP  2011 ) . The economy depends heavily 
on remittances from Haitians  working abroad and on foreign aid. 
 Life expectancy in  Haiti is 62 years, while  infant mortality is 52 per 1,000 live 
births (UNDP  2011 ). Sixty-four percent of Haitians have access to an improved 
water source (i.e., one that is protected from outside contamination), but just 26 % 
have access to improved  sanitation (i.e., a facility that separates human excreta from 
human contact) (WHO/UNICEF  2013 ). Communicable diseases, including  HIV/
AIDS , tuberculosis,  diarrheal diseases , and malaria remain substantial causes of 
disability and death. There are severe shortages of physicians, nurses, hospital beds, 
and essential medicines. About 6 % of GDP is spent on health, of which three- 
quarters is private expenditure. Out-of-pocket spending on health care is extremely 
high (UNDP  2011 ). 
 Haiti has a long history of  political instability, characterized by multiple coups, for-
eign interference and occupation, and extended periods of dictatorship, notably under 
François Duvalier (Papa Doc) and his son Jean-Claude Duvalier (Baby Doc) between 
1957 and 1986. Following a coup in 2004, the U.N. stationed peacekeepers in Haiti. The 
U.N. Stabilization Mission in Haiti (MINUSTAH) has been in Haiti ever since. 
 In January 2010, a magnitude 7.0 earthquake struck  Haiti . Hundreds of thousands 
of people died and up to a million were left homeless. International aid agencies, 
donor  governments , and  nongovernmental organizations (NGOs) mobilized rapidly 
in response, and substantial amounts of money and aid were promised to assist in 
rebuilding. 
8.9.2  Case Description 
 In mid-October 2010, upstream of the Artibonite River, a sudden rush of people 
began presenting at the local hospital with acute diarrhea, signaling the fi rst cholera 
cases. People living nearby use the river extensively for washing, bathing, and 
drinking water; farmers downstream use it for irrigation. Within days, the spread of 
cholera to the Artibonite River Delta and settlements on the coast had overwhelmed 
local clinics and hospitals. The facilities lacked cholera cots that allow patients to 
defecate hygienically from their beds, while insuffi cient space for all patients pre-
vented isolation of cholera victims. For the thousands of sufferers, the supply of 
13  Purchasing power parity in 2011 U.S. dollars. 
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doctors, nurses, and rehydration packs proved inadequate. The epidemic exploded 
across  Haiti . Since cholera was not endemic, the  population lacked immunity. 
Within months, thousands of people had died and hundreds of thousands had been 
sickened. 
 NGOs and some international donor  agencies , including from the U.N., who 
were already in  Haiti dealing with the aftermath of the earthquake, diverted resources 
to combat cholera. They distributed medical supplies, organized educational cam-
paigns on cholera  prevention , trucked clean drinking water and water purifi cation 
tablets across the country, and worked with local hospitals to institute rigorous 
infection control measures. 
 The Haitian and international response to the cholera outbreak rapidly brought 
the case fatality rate from around 9 % to less than 1 %. Although the outbreak died 
down, the aid efforts failed to rectify the dire state of  Haiti’s water and  sanitation 
infrastructure. During the rainy season, cases would spike again, exposing the dif-
fi culty of improving the Haitian health care system so that it could respond to new 
outbreaks without external assistance. 
 Haiti had been cholera-free for more than a century—so how had cholera got 
there? Almost as soon as the outbreak started, rumors circulated blaming U.N. 
peacekeepers. A contingent of soldiers from Nepal, where cholera is endemic, had 
arrived in October 2010. They were stationed at a camp on a tributary of the 
Artibonite River near where the outbreak began. Waste management at the base was 
rumored to be inadequate and had allowed sewage to fl ow into the river. 
 Initially, U.N. offi cials denied responsibility for bringing cholera to  Haiti . But 
rumors and public protest persisted, fueled by independent investigations suggest-
ing the camp as the source (Piarroux et al.  2011 ). Finally, the U.N. Secretary General 
convened an independent panel of experts charged with determining the source of 
the cholera outbreak. The panel completed its report in May 2011. It argued that the 
evidence from the Artibonite River’s tributary system, the epidemiological timeline, 
and genetic analyses of Haitian  V. cholerae bacteria indicated that the outbreak 
resulted from contamination of the river with feces carrying a strain of the current 
South Asian bacterium. Moreover, the report noted that the “haphazard” plumbing 
construction in the main toilet and showering area offered signifi cant potential for 
cross-contamination, and that heavy rains could cause the open septic pit into which 
black water was deposited to overfl ow into the tributary (Cravioto et al.  2011 ). 
 The report offered a series of recommendations to prevent similar occurrences 
and concluded
 The introduction of this  choler a strain as a result of environmental contamination with feces 
could not have been the source of such an outbreak without simultaneous water and  sanita-
tion and health care system defi ciencies. These defi ciencies, coupled with conducive envi-
ronmental and epidemiological conditions, allowed the spread of the  Vibrio cholerae 
organism in the environment, from which a large number of people became infected. 
 The independent panel concludes that the  Haiti cholera outbreak was caused by the 
confl uence of circumstances as described above and was not the fault of, or deliberate 
action of, a group or individual (Cravioto et al.  2011 ). 
 Since the initial outbreak, more than 7,500 Haitians have died from cholera and 
more than 600,000 have been sickened. Subsequent independent genetic analysis 
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confi rmed that the Haitian strain was almost identical with the strain currently cir-
culating in South Asia (Hendriksen et al.  2011 ). 
 Many commentators believe that the systemic defi ciencies that enabled the out-
break are partly the fault of the Haitian government. It failed to take appropriate 
measures to protect its  population from disease, such as improving drinking water 
and  sanitation , investing in health care infrastructure, and so forth. The Independent 
Panel concluded that the introduction of cholera by the U.N. mission was therefore 
not the fault of the U.N. An alternative view is that multiple actors were at fault for 
this tragedy, including the Haitian government, the U.N., and foreign  governments 
whose  policies affect  Haiti . 
 A distinct issue is whether and how the victims of the outbreak should be compen-
sated. One option is to make  compensation the responsibility of those at fault, although 
the diffi culties in assigning fault may make this option challenging. An alternative is 
to establish a no-fault scheme that would compensate anyone affected, but determin-
ing who must pay is also problematic. Donors working on earthquake relief in  Haiti , 
for example, arguably should not have to divert funds to remedy a problem they did 
not create. In November 2011, a legal suit was brought against the U.N.  seeking  com-
pensation for the victims of the cholera outbreak (Sontag  2012 ). In February 2013, the 
U.N. invoked legal immunity against such suits and refused to provide 
compensation. 
8.9.3  Discussion Questions 
 1.  Which parties’ interests are affected by the cholera outbreak? Which parties 
might have some responsibility to respond to the outbreak? 
 2.  The U.N.’s Independent Panel of Experts concluded that “the  Haiti cholera out-
break was caused by the confl uence of circumstances … and was not the fault of, 
or deliberate action of, a group or individual.” Assume that they are correct about 
the facts. Does it follow that no one is morally at fault? Explain why or why not. 
 3.  Imagine that you are providing recommendations for compensating the victims 
of  infectious disease outbreaks, like Haiti’s. Should individual actors be held 
accountable, or should a no-fault compensation scheme be put in place? If the 
latter, who should provide  compensation ? Explain the reasons for your responses. 
(Douglas  2009 discusses “no-fault” compensation in another context.) 
 4.  If the Haitian government has neglected its responsibilities to its citizens, does 
this make any difference to the help that international aid agencies should pro-
vide to Haiti? Explain why or why not. 
 5.  One possible concern with seeking compensation for the people who contracted 
cholera is that it may have a “chilling effect” on international assistance. For 
example, if aid agencies believe they are at  risk of being sued for unintentionally 
transmitting disease, they may be deterred from working in a country in the fi rst 
 place . Should the Haitian government or the lawyers representing the victims 
take this concern into account? Why or why not? 
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 This case is presented for instructional purposes only. The ideas and opinions 
expressed are the authors’ own. The case is not meant to refl ect the offi cial position, 
views, or  policies  of the editors, the editors’ host institutions, or the authors’ host 
institutions . 
8.10.1  Background 
 During the last century, public health practices have greatly improved the health of 
individuals and societies in the  Middle East and North Africa (MENA) region 
through successful interventional programs like expanded immunization for  chil-
dren and universal salt iodization programs. The major challenge for public health 
in the twenty-fi rst century is to simultaneously maintain and upgrade the infrastruc-
ture created to improve peoples’ lives. 
 Currently, the MENA  region faces multiple challenges to its public health achieve-
ments, one of which is the impact of sanctions being used against MENA countries to 
infl uence  political behavior. Sanctions—defi ned as mostly economic but also political 
and military  penalties introduced to alter political/military threats and behavior—are 
employed by the  United States and other countries to discourage the proliferation of 
weapons of mass destruction and ballistic missiles, bolster  human rights , end  terror-
ism , thwart drug traffi cking, discourage armed aggression, promote market access, 
protect the environment, and replace  governments (Haass  1998 ). Sanctions often 
involve  economic measures , such as restricting or eliminating  foreign assistance , 
freezing countries’ assets, imposing export and import limitations, and revoking most-
favored-nation  trade  status (World Health Organization  2003 ). 
 Empirical evidence indicates that sanctions have profound long- and short-term 
public health impact on the health of citizens in the affected countries, with the great-
est  harm affecting the elderly, women, and  children (Garfi eld  1999 ; Ali and Shah 
 2000 ). This impact goes far beyond problems with medical supplies or other health-
specifi c resources.  Public health services depend on a safe water supply, a functioning 
 sanitation system, and a reliable  power infrastructure; on availability of equipment 
such as  ambulances , X-ray machines, and refrigerators for storing  vaccines ; on the 
public having resources to access health care (e.g., transportation, fi nancial resources); 
and on human resources, the trained staff who use the equipment. 
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 Two examples of the use of sanctions were those imposed by the  United Nations 
(U.N.) against  Iraq in the 1990s and against  Syria beginning in 2011. 
8.10.2  The Case of  Iraq 
 To assess the health impact of the Iraq sanctions, the U.N. Children’s Fund 
(UNICEF), in  collaboration with the World Health  Organization and local health 
authorities surveyed  child health in Iraq during February through May 1999 
(UNICEF  1999a ,  b ). Between 1984 and 1989,  infant mortality in Iraq was 47 per 
1,000 live births (Ali and Shah  2000 ). In southern and central Iraq, the infant mor-
tality rate almost tripled, rising to 108 per 1,000 live births during 1994 through 
1999. The under-5 child mortality rate also drastically increased (more than dou-
bled) from 56 to 131 per 1,000 live births for the same period (Ali and Shah  2000 ). 
Yet in the autonomous northern region of Iraq,  infant mortality declined from 64 to 
59 per 1,000 live births and under-5 mortality fell from 80 to 72 per 1,000 live births 
for the same period. These differences were attributed to better food and  resource 
allocation due to  Western support for an autonomous region and the nonapplication 
of universal sanctions (UNICEF  2002 ). 
 Other studies of the health impact of sanctions on  Iraq have similar negative fi nd-
ings (Armijo-Hussein et al.  1991 ; Hurwitz and David  1992 ; Central Statistical 
Organization, Iraq  1996 ,  1997 ). Table  8.1 summarizes data from these studies and 
shows the change in health indicators once sanctions were imposed in 1990.
8.10.3  The Case of  Syria 
 Since May 2011, economic sanctions against Syria signifi cantly affected the 
exchange rate, devaluing its Syrian Lira (SL). The exchange rate of 45 SL for every 
U.S. dollar increased to more than 200 SL and had serious economic ramifi cations. 
The  cos t of living essentials such as gas, eggs, milk, bread, and cooking oil more 
than tripled over the past 2 years. At the same time, the purchasing  power of 
 Table 8.1  Health status indicators before and after the 1990 sanctions against  Iraq 
 Indicator  1985  1991  1996 
 Infant mortality rate  52  42  97 
 Under-5 mortality rate  64  42  126 
 Chronic malnutrition (%)  18  18  32 
 Stunting (%)  12  29  26 
 Maternal mortality per 100,000 
births 
 –  121  294 
 Diarrhea episodes per child per year  –  3.8  14.4 
 Births below 2.5 Kg (%)  5–9  4.5  12 
 Note. A dash indicates that reliable data are not available 
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salaries was halved. Families, nearing starvation, were forced out of work, and 
more than 20 % of the working  population was unable to purchase living essentials 
(Zarzar  2013 ; Food and Agriculture Organization of the United Nations  2013 ). The 
collapse of the exchange rate increased the cost of health services and of medicines. 
Despite the emphasis of sanctions on  economic measures , they prevented entry of 
essential medical supplies into the country, including those for chronic diseases 
such as cancer,  diabetes , and heart disease, which are not produced locally. Local 
drug production, an area in which Syria had been 90 % self-suffi cient before the 
sanctions and  confl ict , largely collapsed. This opened channels for counterfeit 
drugs and corruption among those who smuggled supplies through the country’s 
porous borders. The high  cost of heating and electricity during 2 years of  confl ict 
compounded the adverse effects of Syria’s extreme winter and summer tempera-
tures. Most notably, the cold chain of  vaccines were destroyed, contributing to the 
virtual collapse of the once successful  vaccination programme (Al Faisal et al. 
 2012a ,  b ). The combination of price increases, job losses, and lower salaries devas-
tated families, especially those with  children or members who were pregnant or 
elderly (United Nations Offi ce for the Coordination of Humanitarian Affairs  2013 ). 
Millions of small businesses collapsed in Syria. Many were small-scale and home-
based, run by women providing invaluable income to cope with price infl ation and 
to purchase food,  school books and uniforms for children, and essential medicines 
and emergency medical care. 
8.10.4  Ethical Considerations 
 Before World War I, economic sanctions were considered acts of warfare that, like 
military sieges, infl icted suffering on entire  populations . Viewed this way, economic 
sanctions appear ethically suspect from a number of perspectives. Sanctions violate 
the just war ban on targeting noncombatants, the Kant’s philosophy not to use peo-
ple as means to an end, and the  negative right of populations not to be deprived of 
their means of subsistence (Gordon  1999 ; United Nations  2005 ). However, after 
World War I when the League of Nations was created, economic sanctions came to 
be viewed as a peaceful, diplomatic alternative to war  t hat could prevent military 
intervention (Gordon  1999 ). This viewpoint holds that to justify sanctions, the ben-
efi ts of avoiding the presumably far greater  harms caused by war, civil war, or long- 
term  political oppression must outweigh the harms sanctions impose on a populace. 
But this grim utilitarian calculus must also consider the probability of the success of 
sanctions, which generally is low. Pape ( 1997 ), for example, estimates that sanc-
tions lead to political  compliance less than 5 % of the time. More optimistically, 
Hufbauer et al. ( 2009 ) judge sanctions effective in 34 % of situations used. However, 
they stress that the success of sanctions depends on many factors including the pur-
pose; the relative economic instability of the country receiving sanctions; whether 
the country receiving sanctions is part of a broad array of diplomatic, economic, 
military, and covert measures; and whether the sanctions are being imposed in the 
context of a broader international coalition (Hufbauer et al.  2009 ). 
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8.10.5  Case Description 
 You are a public health offi cial from a country in the Middle East researching the 
impact of economic sanctions on the health of  populations . You have seen fi rst-hand 
the impact sanctions have had on  vulnerable populations . You also have expertise in 
public health ethics and have written extensively about ethics in the use of economic 
sanctions. You have been invited by a United Nations  commission to testify on the 
health impact of sanctions. The commission  values your opinion on whether sanc-
tions are ever ethical and justifi ed. 
8.10.6  Discussion Questions 
 1.  What are the range of ethical considerations for and against the use of economic 
sanctions? Are there ways of imposing economic sanctions that can avoid forms 
of collective punishment and minimize subsequent adverse health impact on 
individuals and populations? 
 2.  In extreme situations where many human lives are at stake, such as emergency 
disaster relief, doctors and public health offi cials often revert to simple utilitarian 
calculations of lives lost or saved (e.g.,  triage decisions). To what extent is the 
ethical logic surrounding economic sanctions similar or dissimilar  to the ethical 
logic of emergency disaster relief? 
 3.  Can economic sanctions be ethically justifi ed
 (a)  as an alternative to long-standing  political oppression and human rights 
violations? 
 (b)  to prevent civil war? 
 (c)  to avert war? 
 (d)  to effect regime change? 
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views, or  policies  of the editors, the editors’ host institutions, or the authors’ host 
institutions . 
8.11.1  Background 
 In the  United States ,  regulations for informed consent largely came about during the 
1950s through 1970s not only in response to unethical human experiments carried 
out in Nazi Germany, but also to those within U.S. borders (Beecher  1966 ). 
Experiments like the  U.S. Public Health Service Tuskegee  Syphilis Study (Jones 
 1981 ) prompted Congress to enact human research  regulations , initially through the 
1974 National Research Act. Subsequently, other research  guidelines have been 
developed and revised (World Health Organization  2000 ;  Council for International 
Organizations of Medical Sciences  2002 ; The International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use  1996 ; World Medical Association  2008 ), fostering expansion of ethics 
commissions and review boards and making informed consent an integral compo-
nent of health research (Meslin and Johnson  2008 ). Yet, half a century later, many 
countries still lack adequate  human research regulations or regulatory authorities. 
These regulatory gaps leave research participants, their families, and communities at 
 risk for great  harm through sociocultural  discrimination , research-related illness, dis-
ability, and death and post-experimental medical abandonment. In Nigeria, Pfi zer 
tested an unapproved drug on  infants and  children (Abdullahi v. Pfi zer Inc.  2002 ); in 
 India , Johns Hopkins tested cancer drugs on patients without proper  consent (Sharma 
 2001 ); and other such incidents have been reported (LaFraniere et al.  2000 ). Even the 
U.S. National Institutes of Health failed to produce consent forms for experiments on 
HIV-positive women in developing countries (Public Citizen  1998 ). 
 On a practical and ethical level, debate continues over human  research and 
 informed consent (Tri-Council  2010 ; Marshall  2008 ; Nuffi eld Council on Bioethics 
 2002 ) . While some argue for a single ethical  standard for human research (Lurie 
and Wolfe  1997 ; Angell  1997 ), others believe that imposing a global ethical stan-
dard irrespective of cultural differences would amount to ethical imperialism 
(Resnik  1998 ).  The New England Journal of Medicine “has taken the position that 
it will not publish reports of unethical research regardless of their scientifi c merit” 
(Angell  1997 ). But like other scientifi c journals, it has found diffi culty in determin-
ing what is unethical versus what is culturally appropriate  research in different 
settings. 
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 There are many challenges to obtaining  informed consent . Some involve illiter-
acy; noncomprehension of  information ; language and communication barriers; or 
unfamiliarity with certain scientifi c, medical, or ethical concepts. Other challenges 
are attributable to complex sociocultural, psychological, or structural elements, 
such as shared decision making by community members, rather than by an indi-
vidual (Marshall  2000 ,  2008 ). Some studies, however, take the stance that such 
challenges do not preclude an individual’s ability to understand or voluntarily par-
ticipate in research studies (Pace et al.  2003 ). Consequently, in order to ensure that 
 research  participation is  voluntary , it is important to safeguard a participant’s right 
to refuse or withdraw from a study at any time. 
 One practical solution to obtaining appropriate  consent is by implementing cul-
turally acceptable methods such as oral consent, video  d ocumentation, or commu-
nity  meetings (Tri-Council  2010 ; Nuffi eld Council on Bioethics  2002 ; Dawson and 
Kass  2005 ). Another is to require foreign researchers to receive dual approval 
through a local review board and their own institutional review board (IRB) (World 
Health Organization  2000 ;  Council for International Organizations of Medical 
Sciences  2002 ; Tri-Council  2010 ). Nevertheless,  multinational  collaborations in 
 research , especially those originating in regions that lack adequate research  regula-
tions , can be problematic because research “approval” may not provide adequate 
protections. 
 De-identifi ed data and  information 14 pose an additional complication for obtain-
ing proper  informed consent . These can include “x-rays, endoscopic images, images 
of organs or tissues taken during an autopsy, still or video recordings of surgical 
procedures, and microscopic images” (Tranberg et al.  2003 ). As long as these remain 
de-identifi ed, researchers need not obtain informed  consent (European Union  1995 ; 
U.S. Department of Health and Human Services  2009 ; National Institutes of Health 
 2007 ). However, in countries lacking adequate  research ethics infrastructures, waiv-
ing  informed consent is problematic at several levels. First, verifying if appropriate 
 consent was obtained becomes virtually impossible. Second, the lack of consent can 
be medically dangerous for research participants and have legal repercussions for 
researchers (Flory et al.  2008 ). Finally, it can complicate the  research process by 
compromising the utility of research samples and data (Wendler  2008 ). 
 Continued  globalization , international development and increased accessibility 
to data through electronic medical records and online databases will increase multi-
national human research. As  multinational research becomes more common, the 
need to fi nd appropriate ethical  standards and  informed consent  policies will become 
more urgent. Ultimately, the goal of such standards and policies should be to ensure 
that research participants and their  information are safeguarded at the origin and 
throughout every step of the research process. 
14  De-identifi cation involves stripping data and  information of personal identifi ers (e.g. names, 
addresses, birth dates, photos, or any unique identifi ers), such that an individual’s identity remains 
anonymous and cannot be retraced. 
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8.11.2  Case Description 
 You are an  infectious disease specialist working at a university in a high-income 
country and are interested in researching cervical cancer in immunocompromised 
patients. Because you  collaborate regularly with colleagues worldwide, other 
researchers commonly seek your input. An African colleague e-mails you for advice 
on a multinational cervical cancer study she is conducting with several other research-
ers in seven different African countries. This study began 3 years ago to address the 
local  population’s health needs and has been funded by local hospitals and organiza-
tions. This colleague, a public health  professional , has compiled the  research data in 
an online database. The  information she sends you includes an electronic copy of the 
preliminary report,  de-identifi ed data set , and pathology slides of cervical specimens. 
After reviewing her preliminary fi ndings, you agree that her  research could posi-
tively impact the  health outcomes of individuals in her community. 
 Excited by this initial review, your colleague invites you to coauthor an upcom-
ing manuscript on the study. You carefully review the methods section of the pre-
liminary report, focusing on how  consent was obtained. In one research country, 
consent was provided via video documentation; in two others, it was obtained 
through a standardized consent form; and in a fourth, through verbal consent of 
male community leaders  before seeking consent from individual participants, a 
practice in line with local cultural  norms . For the remaining three countries, no 
consent documentation exists. 
 You follow-up with your colleague about the various consent methods. She indi-
cates that none of the countries involved in the project have  IRBs or national 
research  guidelines , but that  consent methods were typical for research projects in 
these countries. Regarding the three countries lacking consent documentation, she 
believes that some form of consent was obtained from the research participants, 
although she lacks supporting evidence. 
 Although the  information you received was de-identifi ed, you wonder about the 
lack of uniformity in the consent process but attribute it to  respect for differing cul-
tural  norms . Based on all  information provided, you believe the  research has scien-
tifi c merit and the data collected is scientifi cally valid. You also believe the study 
should be published, as it could signifi cantly improve the health of the region and 
advance future research. 
8.11.3  Discussion Questions 
 1.  Who would you turn to in your institution for guidance regarding your involve-
ment in the  research , coauthorship of the manuscript, and other contributions to 
this research study? 
 2.  What are some appropriate ways to obtain  informed consent when conducting 
 research in areas with culture or language different from yours? Name some pros 
and cons to each approach. 
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 3.  Does the use of multiple methods to obtain  consent raise questions about the 
reliability of the data or validity of the research project? Without confi rmation of 
 informed consent , would you consider the publication of this research study to 
be scientifi c misconduct? 
 4.  What are some appropriate ways to obtain  informed consent for research con-
ducted in countries with different consent  standards and requirements? Are there 
instances when one set of requirements should take priority over another? 
 5.  Given  th e multiple methods used to obtain  consent , are you willing to coauthor 
your colleague’s paper? Why or why not? 
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